These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 29784677)
21. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Torekov SS Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921 [No Abstract] [Full Text] [Related]
22. [Results of the LEADER study: current evidence and perspectives in research]. Mannucci E G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):28S-31. PubMed ID: 28151519 [TBL] [Abstract][Full Text] [Related]
23. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
24. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Rosenstein R; Hough A N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944 [No Abstract] [Full Text] [Related]
25. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Edwards JL N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943 [No Abstract] [Full Text] [Related]
26. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Fischereder M; Schönermarck U N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942 [No Abstract] [Full Text] [Related]
27. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Sarafidis PA; Tsapas A N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941 [No Abstract] [Full Text] [Related]
28. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Lachin JM; Inzucchi SE N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940 [No Abstract] [Full Text] [Related]
29. Cardiovascular safety and benefits of GLP-1 receptor agonists. Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093 [TBL] [Abstract][Full Text] [Related]
30. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Wroge J; Williams NT Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946 [TBL] [Abstract][Full Text] [Related]
31. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. Al Yami MS; Alfayez OM; Alsheikh R Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. Ingelfinger JR; Rosen CJ N Engl J Med; 2015 Nov; 373(22):2178-9. PubMed ID: 26605932 [No Abstract] [Full Text] [Related]
33. Preventing cardiovascular events with empagliflozin: at what cost? Naci H; Basu S; Yudkin JS Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682 [No Abstract] [Full Text] [Related]
34. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Madsbad S Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989 [No Abstract] [Full Text] [Related]
35. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review. Widiarti W; Sukmajaya AC; Nugraha D; Alkaff FF Diabetes Metab Syndr; 2021; 15(3):837-843. PubMed ID: 33866119 [TBL] [Abstract][Full Text] [Related]